IgA nephropathy (IgAN) most common symptoms are hematuria and variable degrees of proteinuria, pathological signs that appear to be associated with the glomerulonephritis induced by mesangial deposition of immune complexes. Once persistent proteinuria seems to be a risk factor for progression of renal disease, pharmacological agents that reduce such pathological process, mainly angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are currently under investigation regarding to its benefits in the IgAN therapy. Although recent works have already evaluated the use of ACEIs and ARBs in adult patients with IgAN, no published or registered systematic review or meta-analysis has accessed the efficacy and safety of ACEIs or ARBs for the treatment of IgAN in children. Thus, the purpose of this research paper is to fulfill this important lack in current scientific literature.